Editorial: Nanomedicine development and clinical translation

Affiliations

Editorial

Chuanqi Peng. Front Chem. 2024.

. 2024 Oct 8:12:1458690.

doi: 10.3389/fchem.2024.1458690. eCollection 2024.

No abstract available

Keywords: clinical translation; drug development; nanomedicine; nanoparticle; therapy.

Conflict of interest statement

Author CP was employed by SalioGen Therapeutics.

Editorial on the Research Topic Nanomedicine development and clinical translation

1. Adams D., Gonzalez-Duarte A., O’Riordan W. D., Yang C.-C., Ueda M., Kristen A. V., et al. (2018). Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379 (1), 11–21. 10.1056/NEJMoa1716153 - DOI - PubMed
1. Anchordoquy T., Artzi N., Balyasnikova I. V., Barenholz Y., La-Beck N. M., Brenner J. S., et al. (2024). Mechanisms and barriers in nanomedicine: progress in the field and future directions. ACS Nano 18 (22), 13983–13999. 10.1021/acsnano.4c00182 - DOI - PMC - PubMed
1. Anselmo A. C., Mitragotri S. (2021). Nanoparticles in the clinic: an update post COVID-19 vaccines. Bioeng. Transl. Med. 6 (3), e10246. 10.1002/btm2.10246 - DOI - PMC - PubMed
1. Baden L. R., Sahly H. M. E., Essink B., Kotloff K., Frey S., Novak R., et al. (2021). Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384 (5), 403–416. 10.1056/NEJMoa2035389 - DOI - PMC - PubMed
1. Barenholz Y. (2012). Doxil® — the first FDA-approved nano-drug: lessons learned. J. Control. Release 160 (2), 117–134. 10.1016/j.jconrel.2012.03.020 - DOI - PubMed